NIH-funded study identifies gene variant as potential drug target
Defying the odds, an individual at high risk for early-onset Alzheimer’s disease remained dementia-free for many years beyond what was anticipated. A study funded in part by the National Institute on Aging (NIA), part of the National Institutes of Health, led researchers to suggest that a gene variant may be the key, perhaps providing a new direction toward developing a treatment.
The research focused on the case of a woman who carried a gene mutation known to cause early-onset Alzheimer’s. However, she did not develop signs of the disease until her seventies, nearly three decades after her expected age of onset. The researchers suspect that she may have been protected because in addition to the gene mutation causing early-onset Alzheimer’s in her family, she also had two copies of the APOE3 Christchurch (APOE3ch) gene variant. Findings of this case study as published in Nature Medicine suggest that two copies of the APOE3ch variant, named after Christchurch, New Zealand where it was first identified, may protect against Alzheimer’s.
“Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field,” said NIA Director Richard J. Hodes, M.D. “We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information.”
Early-onset Alzheimer’s disease is rare, representing less than 10% of all people who have Alzheimer’s. It typically occurs between a person’s 30s to mid-60s. Risk for both early- and late-onset Alzheimer’s disease is affected by genetic factors.
For the study, researchers led by investigators at Massachusetts General Hospital, Boston, in collaboration with the University of Antioquia, Medellin, Colombia, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, and Banner Alzheimer’s Institute, Phoenix, looked at genetic data from a Colombian family with more than 6,000 living members. Family members who carry a rare gene mutation called Presenilin 1 (PSEN1) E280A, have a 99.9% risk of developing early-onset Alzheimer’s disease.
The researchers confirmed that the woman in this case carried the PSEN1 E280A mutation, which caused early-onset Alzheimer’s in her other family members. However, she also had two copies of the APOE3ch gene variant, while no other affected family member carried two copies of this variant. Affected family members develop Alzheimer’s in their 40s, but she remained disease free until her 70s. Imaging tests showed that the woman had only minor neurodegeneration. She did have large amounts of amyloid protein deposits, a hallmark of Alzheimer’s disease, in her brain. But the amount of tau tangles, another hallmark of the disease, and the one more correlated with how thinking and memory are affected, was relatively low.
Experiments as part of the study showed that the APOE3ch variant may reduce the ability of APOE to bind to certain sugars called heparan sulphate proteoglycans (HSPG). APOE binding to HSPG has been implicated as one mechanism that may contribute to the amyloid and tau protein deposits that destroy the brain. The research suggests that a drug or gene therapy that could reduce APOE and HSPG binding has the potential to be a new way to treat or prevent Alzheimer’s disease.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Dana Goldman: Progress is on the horizon in Alzheimer's. But will patients get access?on October 7, 2020 at 10:35 am
In March, the FDA will release the eagerly-anticipated results of its priority review of aducanumab -- Biogen and Eisai's investigational treatment for Alzheimer's disease. If approved, this could be ...
- Are You Afraid Of Alzheimer's?on October 7, 2020 at 10:11 am
You could also cut your risk of depression or anxiety by 11 percent. Hearing aids will help you stay socially connected, which may be the one most important step you can take for your overall health, ...
- Chestnut Knoll team walks with purpose to end Alzheimer's diseaseon October 7, 2020 at 8:31 am
One of your neighbors posted in Community Corner. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- Kemper House spokesperson to give talk on Alzheimer's disease, dementiaon October 7, 2020 at 7:54 am
A spokesperson for Kemper House -- a care facility that specializes in Alzheimer’s disease and dementia -- will lead an online program hosted by Mentor Public Library at 2 p.m., Oct. 19. The program, ...
- Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplanton October 7, 2020 at 5:28 am
Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal ...
- Anavex 2-73 And GV-971: Turning The Tide Against Alzheimer's Diseaseon October 7, 2020 at 4:03 am
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the ...
- Two years later: KFOR checks in with young Oklahoma woman battles early onset Alzheimer’son October 6, 2020 at 8:56 pm
News 4 first visited Amanda Rushing in 2018, when Amanda, then 40, shared what it was like to be battling Alzheimer’s at such a young age. And over the past two years, Anna says she’s ...
- Fairfield County WALK To End Alzheimer's Oct. 11on October 6, 2020 at 7:53 pm
The Alzheimer's Association is encouraging people to walk as individuals or in small groups on sidewalks and trails across the state.
- Damage Done by Alzheimer’s Risk Gene May Be Undone by Another Disease-Linked Geneon October 6, 2020 at 11:07 am
New research suggests that the most significant risk-gene associated with Alzheimer’s disease can hinder a crucial process in a specific type of brain cell — and the key to alleviating the ...
- Alzheimer's risk gene disrupts endocytosis, but another disease-linked gene could helpon October 6, 2020 at 8:05 am
In a new study, a team of scientists based at The Picower Institute for Learning and Memory at MIT and the Whitehead Institute for Biomedical Research reveals evidence showing that the most prominent ...
via Bing News